Publications

2010

Gay F, S Rajkumar V, Coleman M, Kumar S, Mark T, Dispenzieri A, et al. Clarithromycin (Biaxin)-lenalidomide-low-dose dexamethasone (BiRd) versus lenalidomide-low-dose dexamethasone (Rd) for newly diagnosed myeloma. Am J Hematol. 2010;85(9):664-9.
Tormey CA, Peddinghaus ME, Erickson M, King KE, Cushing MM, Bill J, et al. Improved plasma removal efficiency for therapeutic plasma exchange using a new apheresis platform. Transfusion. 2010;50(2):471-7.
Rached M-, Kode A, Xu L, Yoshikawa Y, Paik J-, DePinho RA, et al. FoxO1 is a positive regulator of bone formation by favoring protein synthesis and resistance to oxidative stress in osteoblasts. Cell Metab. 2010;11(2):147-60.
Magro CM, Cruz-Inigo AE, Votava H, Jacobs M, Wolfe D, A Crowson N. Drug-associated reversible granulomatous T cell dyscrasia: a distinct subset of the interstitial granulomatous drug reaction. J Cutan Pathol. 2010;37 Suppl 1:96-111.
Gerstein MB, Lu ZJ, Van Nostrand EL, Cheng C, Arshinoff BI, Liu T, et al. Integrative analysis of the Caenorhabditis elegans genome by the modENCODE project. Science. 2010;330(6012):1775-87.
Magro CM, A Crowson N, Mihm MC, Kline M. De novo intraepidermal epithelioid melanocytic dysplasia: an emerging entity. J Cutan Pathol. 2010;37(8):866-9.
Barbieri CE, Lotan Y, Lee RK, Sonpavde G, Karakiewicz PI, Robinson B, et al. Tissue-based molecular markers for bladder cancer. Minerva Urol Nefrol. 2010;62(3):241-58.
Lendvai N, Gnjatic S, Ritter E, Mangone M, Austin W, Reyner K, et al. Cellular immune responses against CT7 (MAGE-C1) and humoral responses against other cancer-testis antigens in multiple myeloma patients. Cancer Immun. 2010;10:4.
Chicas A, Wang X, Zhang C, McCurrach M, Zhao Z, Mert O, et al. Dissecting the unique role of the retinoblastoma tumor suppressor during cellular senescence. Cancer Cell. 2010;17(4):376-87.

Pathology & Laboratory Medicine 1300 York Avenue New York, NY 10065 Phone: (212) 746-6464
Surgical Pathology: (212) 746-2700